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Abstract
Purpose [18F]FDG PET/CT may predict the absence of acute allograft rejection (AR) in kidney transplant recipients (KTRs) 
with acute kidney injury (AKI). Still, the proposed threshold of 1.6 of the mean of mean standardized uptake values (mSU-
Vmean) in the renal parenchyma needs validation.
Methods We prospectively performed 86  [18F]FDG PET/CT in 79 adult KTRs who underwent per-cause transplant biopsy 
for suspected AR. Biopsy-proven polyoma BK nephropathies (n = 7) were excluded. PET/CT was performed 192 ± 18 min 
after administration of 254.4 ± 30.4 MBq of  [18F]FDG. The  SUVmean was measured in both upper and lower poles of the 
renal allograft. One-way analysis of variance (ANOVA) and Tukey’s studentized range test were sequentially performed. 
The receiver operating characteristic (ROC) curve was drawn to discriminate “AR” from non-pathological (“normal” + “bor-
derline”) conditions.
Results The median age of the cohort was 55 [43; 63] years, with M/F gender ratio of 47/39. The mean eGFR was 
31.9 ± 14.6 ml/min/1.73m2. Biopsies were categorized in 4 groups: “normal” (n = 54), “borderline” (n = 9), “AR” (n = 14), 
or “others” (n = 2). The median [min; max]  mSUVmean reached 1.72 [1.02; 2.07], 1.97 [1.55; 2.11], 2.13 [1.65, 3.12], and 
1.84 [1.57; 2.12] in “normal,” “borderline,” “AR,” and “others” groups, respectively. ANOVA demonstrated a significant 
difference of  mSUVmean among groups (F = 13.25, p < 0.0001). The ROC area under the curve was 0.86. Test sensitivity and 
specificity corresponding to the threshold value of 1.6 were 100% and 30%, respectively.
Conclusion [18F]FDG PET/CT may help noninvasively prevent inessential transplant biopsies in KTR with AKI.
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Introduction
The prompt diagnosis of acute kidney allograft rejection 
(AR) is crucial in the management of kidney transplant 
recipients (KTRs) presenting with acute kidney injury 
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(AKI). It currently relies on the histological analysis of a 
renal sample obtained by needle biopsy, following Banff 
classification [1]. In clinical routine, most per-cause trans-
plant biopsies show a normal histology [2]. Therefore, vari-
ous non-invasive diagnostic approaches are under investi-
gation to reduce the systematic usage of allograft biopsies 
[3–5]. More specifically, rodent models of allogeneic kidney 
transplantation (KTx) demonstrated that  [18F]FDG PET/CT 
early and specifically detect AR [6]. In humans, we have 
similarly underscored the putative usefulness of  [18F]FDG 
PET/CT in the diagnosis of AR in a pilot study of 32 KTRs 
with AKI [7]. Our “rule-out” approach was based on the 
mean of mean standardized uptake values  (mSUVmean) in 4 
independent volumes of interest (VOI) of the renal cortex, 
with a diagnostic threshold set at 1.6 to target a negative pre-
dictive value of 100%. In the present validation cohort, we 
prospectively assess this 1.6 threshold of renal  mSUVmean 
in the diagnosis of AR in KTRs with AKI who underwent a 
transplant needle biopsy for suspected AR.
Patients and methods
Patient population and specimens
The study was approved by ULiège IRB (#B707201215598). 
After written informed consent, adult KTRs undergoing a 
transplant biopsy for suspected AR were prospectively 
enrolled between March 2015 and December 2019.
Histopathology
Biopsies were assessed by two pathologists according to 
Banff criteria [1]. Histological lesions were scored as contin-
uous variables (from 0 to 3) based on leukocyte infiltration 
in each component: glomeruli (g); peritubular capillaries 
(ptc); arteries (v); tubules (t); and interstitium (i). Biop-
sies diagnosed as “normal” were defined as a Banff [i + t] 
score < 2 and no features of a disease. Biopsies diagnosed 
as “borderline” were defined as a Banff [i + t] score ≥ 2 
(but < i2-t2 and v = 0) and no feature of a specific disease. 
Biopsies diagnosed as “AR” were defined as a Banff [i + t] 
score ≥ i2 and ≥ t2 and/or v > 0. Biopsies diagnosed as “oth-
ers” were defined as showing features of AR-unrelated dis-
eases. All biopsies were stained for polyoma BK virus.
[18F]FDG PET/CT imaging
The present validation cohort followed exactly the same 
protocol as described in the proof-of-concept study [7]. The 
PET/CT procedure was performed using cross-calibrated 
Philips GEMINI TF Big Bore or TF 16 PET/CT systems 
(Philips Medical Systems, Cleveland, OH, USA) at 191 
[min. 179; max. 254] min following intravenous injection 
of a mean dose of 254.4 ± 30.4 MBq of  [18F]FDG (to purge 
as much as possible the radioactive signal from the urinary 
compartment). No contrast agent or diuretics were infused. 
A low-dose helical CT (5-mm slice thickness, 120-kV tube 
voltage, and 40-mAs tube current–time product) centered 
to the renal transplant was performed, followed by a PET 
emission scanning with 2 bed positions each lasting 4 min. 
Images were reconstructed using iterative list mode time-of-
flight algorithms, and corrections for attenuation, dead-time, 
random, and scatter events were applied. The PET/CT proce-
dure was performed within a 48-h period of the ultrasound-
guided renal transplant biopsy. All  [18F]FDG -PET/CT were 
acquired in fasting conditions before any modification of 
immunosuppressive regimens. The mean glycemia at the 
time of tracer injection was 6.2 ± 1.6 mmol/L. Four VOI 
of 1 ml were manually drawn in the cortical region of both 
upper (n = 2) and lower (n = 2) poles of the renal transplant 
at distance from the pelvicalyceal zone, as described previ-
ously [8]. The  SUVmean was measured in each VOI, with 
no threshold activity, and the mean of these 4  SUVmean was 
calculated  (mSUVmean).
Statistics
Data were expressed as mean ± standard deviation (SD) or 
as median [minimum; maximum]. One-way analysis of vari-
ance (ANOVA) followed by post hoc Tukey’s studentized 
range test was performed to statistically compare  mSUVmean 
values among groups taking into account the necessary cor-
rection for multiple testing. The receiver operating charac-
teristic (ROC) curve was drawn to discriminate “AR” from 
non-pathological (“normal” + “borderline”) conditions. 
The correlation between  mSUVmean and acute composite 
(g + i + t + v + ptc) Banff score was calculated. All analyses 
were done with SAS 9.4.
Results
We performed 86  [18F]FDG PET/CT in 79 KTR with 
AKI. Each suspicion of AR leading to kidney biopsy and 
 [18F]FDG PET/CT imaging was clinically and statisti-
cally independent. The characteristics of the cohort are 
summarized in Table 1. The median age was 55 [43; 63] 
years, with M/F gender ratio of 47/39. The mean eGFR 
was 31.9 ± 14.6 ml/min/1.73m2. Biopsies were described 
as “normal” (n = 54), “borderline” (n = 9), “AR” (n = 14), 
or “others” (n = 2). Biopsy-proven polyoma BK nephropa-
thies (n = 7) were excluded. AR was antibody-mediated 
in 2 cases, whereas T-cell-mediated AR was found in 13 
cases, respectively. The histological finding in the “other” 
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causes of graft failure was focal segmental glomeruloscle-
rosis with no evidence of AR (n = 2). The median [min; 
max]  mSUVmean reached 1.72 [1.02; 2.07], 1.97 [1.55; 
2.11], 2.13 [1.65; 3.12], and 1.84 [1.57; 2.12] in “nor-
mal,” “borderline,” “AR,” and “others” groups, respec-
tively (Fig. 1). ANOVA demonstrated a significant differ-
ence of  mSUVmean among groups (F = 13.25, p < 0.0001) 
(Fig. 2A). The  mSUVmean of biopsy-proven AR was sig-
nificantly higher than “normal” cases (p < 0.05). There was 
no significant difference between “normal” vs. “border-
line” or between “AR” vs. “borderline” groups. A positive 
correlation between  mSUVmean and the acute Banff score 
was found, with adjusted  r2 of 0.41 (p < 0.0001) (Fig. 2B). 
The area under the ROC curve reached 0.86. Test sensitiv-
ity and specificity corresponding to the threshold value of 
1.6 were 100% and 30%, respectively. Of methodological 
note, the Youden index reached 2.073, with a sensitivity 
of 57.1% and a specificity of 96.8%.
Discussion
In the present prospective validation cohort of 86  [18F]
FDG PET/CT performed in 79 KTRs presenting with AKI, 
the previously proposed  mSUVmean threshold of 1.6 sig-
nificantly discriminated non-rejection, with a sensitivity 
of 100% [7]. The poor specificity of  [18F]FDG PET/CT in 
detecting AR is most probably due to the radiotracer which 
accumulates in other inflammatory conditions. Still, the 
renal allografts with biopsy-proven AR were character-
ized by a significantly higher uptake of  [18F]FDG com-
pared to “normal” biopsies, with a Youden index of 2.073 
corresponding to a specificity of 96.8%. From a clinical 
point of view, a high negative predictive value appears 
more appropriate in the management of KTR with AKI 
in order to certify that no diagnosis of AR is missed or 
delayed. The pathophysiological hypothesis of such a pref-
erential accumulation of  [18F]FDG in case of AR relies on 
the increased metabolic activity of infiltrating inflamma-
tory cells, as suggested by the correlation between renal 
 mSUVmean and leucocyte infiltration quantified by the 
acute Banff score [6]. The clinical significance and treat-
ment of borderline changes remain highly debated, which 
prompts the ongoing development and validation of vari-
ous biofluid-based biomarkers of clinically relevant AR [1, 
5]. Note that the ROC curve comparing “normal” biopsies 
versus “biopsy-proven AR” after excluding the borderline 
cases was characterized by an AUC of 0.85, with a cut-off 
of 1.6 corresponding to 100% sensitivity and 30% specific-
ity. All cases with biopsy-proven polyoma BK nephropa-
thy were excluded from our analysis since the diagnostic 
procedure has been standardized via polymerase chain 
reaction (PCR)-based screening for BK virus replication 
in urine and/or blood specimens [9]. Stricto sensu, a nee-
dle biopsy of the renal allograft should only be performed 
after negative PCR results. The median  mSUVmean of the 
allografts with biopsy-proven polyoma BK nephropathy 
was 2.20 [1.96; 2.47].
The limitations of our proposed non-invasive diagnostic 
approach based on  [18F]FDG PET/CT in unstable KTR 
with AKI include (i) the somewhat restricted availability 
of PET/CT machine, (ii) the minor exposure to radiations 
originating from both PET and CT procedures, and (iii) the 
3-h delay between  [18F]FDG injection and image acqui-
sition. Still, the repeatability and reproducibility of the 
quantification of kidney allograft  [18F]FDG uptake have 
been reported as consistent [8]. The use of multiple inde-
pendent VOI distributed right beneath the renal capsule 
in both the upper and lower renal cortices aimed at (i) 
limiting the noise of the urinary  [18F]FDG and (ii) avert-
ing sampling error, which also represents one of the main 
limitations of transplant biopsy [1]. Of technical note, no 
Table 1  Clinical and biological characteristics of the cohort
Data are expressed as mean ± standard deviation; median [interquar-
tile range]
AZA, azathioprine; BMI, body mass index; CIT, cold ischemia time; 
CNI, calcineurin inhibitors; CsA, cyclosporin A; DBD, donor after 
brain death; DCD, donor after circulatory death; DGF, delayed graft 
function; FK, tacrolimus; KTx, kidney transplantation; HLA, human 
leukocyte antigen; LD, living donor; MMF, mycophenolate mofetyl; 
MPA, mycophenolic acid; mTOR, mechanistic target of rapamycin
Cohort
(n = 86 events)
Recipient
 Age (years) 55 [43; 63]
 Gender (male/female; n) 47/39
 BMI (kg/m2) 27 [22; 30]
Donor
 Donor type (n), DBD/DCD/LD 63/17/6
 Age (years) 43 ± 13
 Gender (male/female; n) 40/46
Transplantation
 Rank 1st/ 2nd, or 3rd (n) 79/7
 CIT (min) 644 ± 287
 HLA mismatches, A + B + DR/6 (n) 3 [2; 4]
 Early graft function, immediate/slow/DGF 51/26/9







 mTOR inhibitors: yes/no (n) 4/82
 Steroids: yes/stop (n) 70/16
 Duration KTx at biopsy (days) 279 [28; 1923]
 Donor-specific antibodies: yes/no (n) 14/72
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Fig. 1  Representative  [18F]FDG 
PET/CT imaging in kidney 
transplant recipients with 
biopsy-proven normal histology 
versus acute rejection. Positron-
emission tomography (PET, top 
panels), computed tomogra-
phy (CT, middle panels), and 
combined PET/CT images 
taken after administration of 
 [18F]FDG are shown for kidney 
transplant recipients with biop-
sies showing normal histology 
(left column;  mSUVmean of 
1.5; acute Banff score of 0) or 
T-cell-mediated acute rejec-
tion (right column;  mSUVmean 
of 3.1; acute Banff score of 8). 
The arbitrary scale of standard 


















Fig. 2  Summary of the statistical results of 18F-FDG PET/CT 
analysis. A Boxplot of the mean values of the renal allograft mean 
 SUVmean according to the histopathological categories: normal 
(n = 54); borderline (n = 9); acute rejection (AR) (n = 14); and oth-
ers (n = 2). ANOVA: F-score = 13.25, p-value < 0.0001. B Positive 
correlation between the mean  SUVmean and the acute Banff score 
(R2 = 0.41, p-value < 0.0001)
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difference was statistically detected between the  SUVmean 
of the 4 VOI in the present 86-scan cohort. Assessing the 
global  [18F]FDG accumulation in the renal allograft by 
means of image segmentation software (currently under 
development and validation) would further help to mini-
mize the sampling error.
On the basis of this validation cohort, we postulate that 
 [18F]FDG PET/CT as first-line examination may help save 
selected patients with AKI from undergoing kidney trans-
plant biopsy. Such an invasive procedure would have been 
avoided in 19 cases of our series, which were characterized 
by an  mSUVmean strictly inferior to the 1.6 threshold and 
a normal histology. Further large prospective multicentric 
studies are needed to test whether the  mSUVmean threshold 
of  [18F]FDG PET/CT imaging, in combination with blood 
and urinary biomarkers [3–5], helps to pragmatically dictate 
the need for transplant biopsy in KTR presenting with AKI 
and suspected AR. Other tracers for inflammation may also 
be envisioned in this frequent clinical scenario, such as  [11C]
methionine or  [68 Ga]pentixafor. Standard nuclear medicine 
imaging methods, including MAG3 renal scintigraphy, may 
also provide essential information about perfusion and func-
tion of the kidney in clinical conditions of suspected AR or 
acute tubular necrosis [10].
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